Pathogenesis of Periodontal Disease in Individuals With Psoriasis

Sponsor
Recep Tayyip Erdogan University Training and Research Hospital
Study ID
NCT07158125
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Study Details

The aim of this study is to evaluate the levels of Th17 cell-associated cytokines (IL-17, IL-21, IL-23) and the salivary stress biomarkers cortisol, dehydroepiandrosterone, and Chromogranin A in the pathogenesis of periodontal disease in individuals with psoriasis, thereby revealing immunological and neuroendocrine interactions. The fundamental question it aims to answer is: What are the biological mechanisms that may increase the risk of periodontal disease in individuals with psoriasis? In this context, the periodontal status of individuals with psoriasis will be clinically assessed, followed by analysis of the levels of Th17-associated cytokines and stress biomarkers in gingival crevicular fluid and saliva samples. Additionally, patients will be asked questions from the Social Appearance Anxiety Scale. The periodontal status of individuals with psoriasis will be determined cross-sectionally, and the resulting biomarker levels will be examined. In addition, the data obtained will be evaluated with statistical analysis in relation to disease severity and clinical parameters.

Key Dates

First listed
Sep 5, 2025
Start date
Sep 15, 2025
Status verified
Aug 2025
Primary completion
Feb 2, 2026
Completion
Apr 6, 2026

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: No psoriasis severity
    Patients with a PASI (Psoriasis Area and Severity Index) score of 0
  • Arm: Mild psoriasis severity
    Patients with a PASI (Psoriasis Area and Severity Index) score of 1-10
  • Arm: Moderate psoriasis severity
    Patients with a PASI (Psoriasis Area and Severity Index) score of 10-20
  • Arm: Severe psoriasis
    Patients with a PASI (Psoriasis Area and Severity Index) score of \>20

Primary Outcome Measure

Gingival Crevicular Fluid (GCF) Collection [ Time Frame: Day 1 ]

Central Contacts

Find similar trials

Nationwide
Psoriasis trialsDermatology trialsRheumatology trialsAutoimmune disease trials

Related Studies